PT UBC Medical Indonesia Tbk (LABS.JK)
Jakarta · IDR · Healthcare · Medical Devices
IDR 127 (-0.78%) as of
Key statistics
- Market cap
- 501.65B
- Dividend yield
- 0.00%
- 52-week range
- 126.00 – 260.00
- Beta
- -0.17
- Revenue (TTM)
- 207.82B
- Profit margin
- 5.14%
- Volume
- 259.60k
About PT UBC Medical Indonesia Tbk
PT UBC Medical Indonesia Tbk distributes medical devices in Indonesia. It operates in two segments, Medical Disposables and Consumables; and Diagnostics and Equipment. The company offers NeoMoDX molecular system; Revvity SARS-COV-2 RT PCR and Geneproof SARS-COV-2 PCR KIT; Airdoc Retina AI, a screening technology that uses Artificial Intelligence (AI) to detect chronic diseases such as diabetic retinopathy and hypertension; Hisky; and All-in-one GP workstation. It also provides TB management products, such as Quantiferon TB Hold Plus, Genoscholar, and Ina TB; QIAstat-DX Analyzer; and newborn screening products, including GSP Neonatal and Delfia Neonatal Kit, Neonatal Sampling Paper, and Victor2 D; and Care HPV System and Hybrid Capture 2 - HPV DNA Test. In addition, the company engages in the wholesale of laboratory equipment, pharmaceutical equipment, and medical equipment for human beings and animals; and provision of chemical products and traditional medicine. It serves hospitals, clinical laboratories, and diagnostic centers, as well as central general hospitals, private hospitals, regional public hospitals, the ministry of health, and other ministries. The company was founded in 2014 and is based in Jakarta Timur, Indonesia. PT UBC Medical Indonesia Tbk is a subsidiary of PT Optel Investama Mulia.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Jakarta Timur, Indonesia
- Employees
- 54
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.